Figure 1.

In vivo anti-tumor activity of cancer immunotherapies. (a) IFNγ Venus mice (5 mice per group) were subcutaneously injected with B16 melanoma cells (5 × 10⁵). Tumor volumes were measured every other day. Mice were untreated or given 200 μg of monoclonal antibodies against PD-1, CTLA-4, 4-1BB, CD4 or the combination of anti-PD-1 and anti-4-1BB (anti-PD-1/4-1BB) on days 5 and 9. The graphs show tumor volume of individual mice. (b) Tumor volumes at day 14 were compared. Data are representative of two experiments with 5 mice per group. Dunnett’s test was used for multiple comparisons between control and treatment groups.*p < 0.05, **p < 0.01.